Full Press Release Details
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer.
IDYA
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Key Takeaway: IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE574, a Potential First In Class Dual Inhibitor of KAT6 7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Price reaction · baseline $32.74 (2026-04-02 close) · clean, no other IDYA news in the window
day 0 close
-1.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma